齐拉西酮注射液治疗精神分裂症急性期症状后续药物的研究

目的：评价精神分裂症急性期激越患者在齐拉西酮注射液治疗3d延用不同口服药物的疗效及安全性。方法：符合ICD-10精神分裂症诊断标准，且急性期注射3d齐拉西酮注射液治疗的患者，随机分配到齐拉西酮试验组（试验组）和利培酮试验组（对照组）各30例，对患者进行基线（最后一针齐拉西酮注射后2h）评价，以及肌注治疗后的72h、2周、4周和8周的评价。采用B}JRs量表评价主要疗效，采用副反应症状量表（TESS量表）评定药物的不良反应。结果：两组均口服药物治疗2周时，两titBPRS评分有显著性差异（P〈0．05），其余时间点两组主要疗效指标差异无统计学意义（P〉0．05）。8周时试验组治疗总有效率为80．0％，对照组治疗总有效率为76．7％。试验组药物不良反应较对照组明显减少，TESS量表评分在治疗前后差异无统计学意义（P〉0．05）；对照组出现锥体外系不良反应、体重增加、月经紊乱较多，治疗前后差异有统计学意义（P〈0．05）。结论：甲磺酸齐拉西酮注射液快速有效控制精神分裂症激越症状后，换用齐拉西酮口服疗效与换用利培酮疗效相当，但齐拉西酮安全性更高，不良反应更少。

Study of differentoral drugs afterziprasidone injection in the treatment of agitated schizophrenia in acute phase

Objective： To evaluate the efficacy and safety of 3 -dayziprasidone injection followed by differentoral drugs in the treatment of agitated schizophrenia in acute phase. Method： Patients in acute phase who conform to ICD -10 schizophrenia diag- nostic criteria are treated withziprasidone injection for 3 days, and then are randomlyassigned toziprasidonetreatmentgroup （test group） and risperidone group （control group）. Baseline evaluation （2h after last injection） and evaluation of 72 h, 2 weeks, 4weeks, and 8 weeks after intramuscular injection arc ran on the patients. BPRS scale is used to evaluate the efficacy, and the e- mergent symptoms scale （TESS scale） is used to evaluate the adverse reaction. Result： Each group has 30 subjects,after 2 weeks＇ oral drug treatment, the two groups have significant difference in BPRS score （P 〈 0.05 ）. But for the rest time points, the main efficacy index shows no statisticallysignificant difference between the two groups （ P 〉 0.05 ）. Adverse reaction of test group is much less than that of control group. TESS score shows no significant difference before and after the treatment （ P 〉 0.05 ） ; control group shows extrapyramidal adverse reactions, weight gain, and more menstrual disorder, there is statistically significant difference before and after treatment （ P 〈 0.05 ）. Conclusion ： When agitated symptom of schizophreniais fast and effectivelycontrolled byzi- prasidonemesylate Injection, replacement for treatment withoral ziprasidoneor risperidone shows similar efficacy, but the former has higher safety and less adverse reaction.